Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma

Autor: HELVACı, K, OZTOP, İ, TURAN, Nuriye Burçin, ALGıN, E, ULGER, S, DOGAN, E, BERK, V, BALAKAN, O, EKINCI, AŞ, UYSAL, M, PETEKKAYA, İ, TONYALı, Ö, DANE, F, ÇETIN, B, Aldemir, Mehmet Naci, UNER, A, OZDEMIR, N, COSKUN, U, OZET, A, BUYUKBERBER, S, Anatolian, Society, TUFAN, G, TURKMEN, E, URAKCI, Z, BENEKLI, M, UNAL, OU, EREN, T, OZTURK, SC, BABACAN, NA, UNEK, İT, TOPCU, TO, TASTEKIN, D, USTAALIOGLU, BO, UYSAL, OS, ERCELEP, OB, TASKOYLU, BY, AKSOY, A, CANHOROZ, M, DEMIRCI, U

Background: We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma (PAC). Methods: A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and 2013. Result

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::00f4c031629afc389c061e99e48ee2fc
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/10531

Can assessment of disease burden and quality of life based on mobility level in patients with end-stage cancer provide an insight into unmet needs? An exploratory cross-sectional study.

Autor: Bahar-Ozdemir Y; Department of Physical Medicine and Rehabilitation, Health Sciences University Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey., Kaya S; Department of Physical Medicine and Rehabilitation, Arnavutkoy State Hospital, Istanbul, Turkey., Babacan NA; Department of Clinical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Al T; Emergency Medicine Clinic, Mardin State Hospital, Mardin, Turkey., Albayrak E; Department of Internal Medicine, Ammerland Klinik GmbH, Westerstede, Germany., Coskun N; Department of Anesthesiology and Reanimation, Sancaktepe Sehit Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey., Akyuz G; Department of Physical Medicine and Rehabilitation and Division of Pain Medicine, Marmara University School of Medicine, Istanbul, Turkey.

Publikováno v: Physiotherapy theory and practice [Physiother Theory Pract] 2023 Jun; Vol. 39 (6), pp. 1141-1151. Date of Electronic Publication: 2022 Jan 31.

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.

Autor: Eroglu Z; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA zeynep.eroglu@moffitt.org.; University of South Florida, Tampa, Florida, USA., Broman KK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.; University of South Florida, Tampa, Florida, USA., Thompson JF; Melanoma Institute Australia, North Sydney, New South Wales, Australia., Nijhuis A; Melanoma Institute Australia, North Sydney, New South Wales, Australia., Hieken TJ; Department of Surgery, Mayo Clinic, Rochester, New York, USA., Kottschade L; Department of Surgery, Mayo Clinic, Rochester, New York, USA., Farma JM; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Hotz M; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Deneve J; Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Fleming M; Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA., Bartlett EK; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Sharma A; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Dossett L; Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA., Hughes T; Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA., Gyorki DE; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Downs J; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Karakousis G; Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Song Y; Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Lee A; Department of Surgery, New York University, New York, New York, USA., Berman RS; Department of Surgery, New York University, New York, New York, USA., van Akkooi A; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Stahlie E; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Han D; Division of Surgical Oncology, Oregon Health and Science University, Portland, Oregon, USA., Vetto J; Division of Surgical Oncology, Oregon Health and Science University, Portland, Oregon, USA., Beasley G; Department of Surgery, Duke University, Durham, North Carolina, USA., Farrow NE; Department of Surgery, Duke University, Durham, North Carolina, USA., Hui JYC; Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA., Moncrieff M; Norfolk and Norwich University Hospital, Norwich, UK., Nobes J; Norfolk and Norwich University Hospital, Norwich, UK., Baecher K; Department of Surgery, Emory University, Atlanta, Georgia, USA., Perez M; Department of Surgery, Emory University, Atlanta, Georgia, USA., Lowe M; Department of Surgery, Emory University, Atlanta, Georgia, USA., Ollila DW; Department of Surgery, University of North Carolina, Chapel Hill, North Carolina, USA., Collichio FA; Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA., Bagge RO; Department of Surgery, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden., Mattsson J; Department of Surgery, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden., Kroon HM; Department of Surgery, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia., Chai H; Department of Surgery, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia., Teras J; North Estonia Medical Centre Foundation, Tallinn, Estonia., Sun J; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Carr MJ; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Tandon A; University of South Florida, Tampa, Florida, USA., Babacan NA; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Kim Y; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA., Naqvi M; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA., Zager J; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.; University of South Florida, Tampa, Florida, USA., Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA.; University of South Florida, Tampa, Florida, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Aug; Vol. 10 (8).

BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma.

Autor: Babacan NA; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Peguero E; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Forsyth P; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Eroglu Z; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

Publikováno v: The oncologist [Oncologist] 2021 Oct; Vol. 26 (10), pp. e1887-e1889. Date of Electronic Publication: 2021 Jul 17.

Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma.

Autor: Ercelep O; Department of Medical Oncology, Pendik Education and Research Hospital, Marmara University, Istanbul, Turkey., Alan O; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Telli TA; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Tuylu TB; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Arıkan R; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Demircan NC; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Simsek ET; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Babacan NA; Department of Medical Oncology, Pendik Education and Research Hospital, Marmara University, Istanbul, Turkey., Kaya S; Department of Medical Oncology, Pendik Education and Research Hospital, Marmara University, Istanbul, Turkey., Dane F; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Bozkurtlar E; Department of Pathology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Ones T; Department of Nuclear Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey., Lacin T; Department of Thoracic Surgery, Faculty of Medicine, Marmara University, Istanbul, Turkey., Yumuk PF; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey.

Publikováno v: Tumori [Tumori] 2021 Jun; Vol. 107 (3), pp. 231-237. Date of Electronic Publication: 2020 Sep 02.